Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05097378
Other study ID # PREMIUM
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2022
Est. completion date January 31, 2024

Study information

Verified date October 2021
Source Cambridge University Hospitals NHS Foundation Trust
Contact Lisa Bax
Phone +44 (0)1223 348090
Email lisa.bax@addenbrookes.nhs.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.


Description:

A phase II, multi-centre, open label, randomised trial. The trial will assess the delivery, response rate, treatment compliance, efficacy and safety of encorafenib and binimetinib compared to standard adjuvant therapy in patients with BRAFV600 mutant clinically detected AJCC stage III(B/C/D) or oligometastatic stage IV Melanoma.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 45
Est. completion date January 31, 2024
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent to participate - Aged = 18 years old - AJCC 8th edition stage III (B/C/D), or extracranial oligometastatic stage IV BRAFV600 mutant melanoma, based on histological/cytological and radiological assessments for which surgery is planned, and resection is expected to remove all known tumour(s) with R0 resection margins. 'Oligometastatic stage IV' is defined for the purpose of this trial as M stage disease confined to a single body organ excluding the brain that can be readily removed surgically with anticipated clear margins - For stage III patients, confirmation of no evidence of distant metastatic disease using preferred imaging modalities including CT body or PET/CT and CT or MRI head - For stage IV patients, confirmation of no evidence of unresectable metastatic disease, or metastatic disease in more than 1 body organ, using preferred imaging modalities including CT body or PET/CT and CT or MRI head. The site of metastasis should not be in bone, or CNS, or in any other body site where complete resection is not feasible - The planned resectable disease must be radiologically measurable using standard imaging modalities. - Baseline tumour assessments must be done within 28 days prior to randomisation - BRAF V600E or V600K mutation confirmation - Received no prior BRAF or MEK inhibitors - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Predicted life expectancy >12 months - Normal QTc interval (<480msec) on ECG and left ventricular ejection fraction within normal limits, assessed by echocardiogram or MUGA - Adequate bone marrow function defined as: - Absolute neutrophil count (ANC) =1.5 x 109 /L - Haemoglobin (Hb) = 90 g/L - Platelets =100 x 109 /L - Adequate liver function defined as: - Aspartate aminotransferase (AST) and/or alanine transaminase (ALT) =2.5 x upper limit of normal range (ULN) - Total bilirubin <1.5 x ULN (except if the patient has Gilbert Syndrome or liver metastases, in which case the bilirubin must be <3 x ULN) - Adequate renal function defined as: - a serum creatinine =1.5 x ULN or - calculated creatinine clearance by Cockcroft-Gault of =40 mL/min - Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, completion of QoL and PROM questionnaires and other procedures described in the protocol - Women of child-bearing potential (WCBP) and all sexually active male patients must agree to use effective contraception methods throughout treatment - Be able to swallow the trial medication - Confirmation of adequate diagnostic tumour tissue available for research studies Exclusion criteria - Prior adjuvant therapy for resected primary or loco-regional melanoma - Other invasive malignancies diagnosed within the last 2 years which are not in complete remission, or for which additional therapy is required - Brain or bone metastases - Non-cutaneous primary site of melanoma - Prior radiotherapy to the site planned for surgery - History or current evidence of retinal vein occlusion (RVO) or risk factors for RVO (uncontrolled glaucoma, ocular hypertension, history of hyperviscosity, or hypercoagulability syndromes) - Left ventricular function <50% - Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk or interfere with the trial. Examples include, but are not limited to: - Patients with uncontrolled ischaemic heart or other cardiovascular event (myocardial infarction (MI), new angina, stroke transient ischaemic attack (TIA), or new congestive cardiac failure (CCF)) within the last 6 months - Uncontrolled hypertension - Patients with stable but significant cardiovascular disease defined by heart failure (New York Heart Association Functional Classification (NYHF) III or IV or frequent angina - Patients with baseline QTC interval > 480 msec on electrocardiogram (ECG) - Left ventricular ejection fraction below the lower limit of normal - Presence of active infection - Cirrhotic liver disease, known chronic active or acute hepatitis B, or hepatitis C - Known allergy or hypersensitivity to Encorafenib or Binimetinib, or their excipients. Binimetinib contains lactose, so patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption will be excluded. - Women who are pregnant, plan to become pregnant or are lactating during the trial period - Use of any other investigational anti-cancer drugs (a washout period of 28 days would be required) - Use of strong inducers and inhibitors of CYP3A4 (Appendix 4 - Prohibited Medication) - Known HIV or active Hep B or Hep C infection - Patients who have neuromuscular disorders associated with elevated creatine phosphokinase (CK, e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy) - Autoimmune conditions requiring regular or intermittent use of any systemic steroid or immunosuppressive drugs, with the exception of steroid inhalers - Any immunotherapy in the last 3 months - Prior radiotherapy to the site of disease planned for resection - Concurrent participation in an interventional clinical trial (observational studies allowed)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Encorafenib + Binimetinib
Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K). Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity
Standard Adjuvant Treatment
Standard Adjuvant Treatment

Locations

Country Name City State
United Kingdom Addenbrooke's Hospital Cambridge England

Sponsors (2)

Lead Sponsor Collaborator
CCTU- Cancer Theme Pierre Fabre Medicament

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological response rate % of patients with a complete response using Haemotoxylin and Eosin staining of tumour removed at surgery. During scheduled surgery
Secondary Treatment compliance Incidence of missed treatment doses assessed from number of tablets returned. Through study completion for an average of 12 months
Secondary Radiological response % of patients with a complete response using CT scan tumour measurement assessment (RECIST) from start of treatment until 8 weeks. Through study completion for an average of 12 months
Secondary Toxicity of treatment Rate of patients with drug related toxicities reported from start of study until end of treatment Through study completion for an average of 12 months
Secondary Lymphoedema toxicity Incidence of lymphoedema toxicity using circumferential limb measurement and questionnaires for an average of 12 months. Through study completion for an average of 12 months
Secondary Survival rate Number of patients deceased from start of treatment for an average of 12 months. Through study completion for an average of 12 months
Secondary Quality of life Quality of life assessed by Functional Assessment of Cancer Therapy - Melanoma (FACT-M) questionnaire for an average of 12 months. Through study completion for an average of 12 months
Secondary Recruitment rate Rate of monthly recruitment achieved during the last 6 months of the trial recruitment period Through study completion for an average of 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients